Zosyn Is Cleared for Treatment Of Nosocomial Pneumonia

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam) is now indicated for use in treating moderate to severe nosocomial pneumonia caused by piperacillin-resistant beta-lactamase-producing strains of Staphylococcus aureus. In a multicenter study of 300 patients with nosocomial pneumonia, the rate of clinical cure or improvement for Zosyn plus tobramycin was 74%, compared with 50% for cef-tazidime plus tobramycin, the company said.

ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam)is now indicated for use in treating moderate to severe nosocomialpneumonia caused by piperacillin-resistant beta-lactamase-producingstrains of Staphylococcus aureus. In a multicenter study of 300patients with nosocomial pneumonia, the rate of clinical cureor improvement for Zosyn plus tobramycin was 74%, compared with50% for cef-tazidime plus tobramycin, the company said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content